The IHU Cesti is committed to enhancing patient health as well as its clinical management by innovative strategies such as organ, cell and gene transplantation.

The major aims of the Cesti program are the following :

 (1) to better understand the cellular and molecular mechanisms of acute and chronic graft loss or of GVHD disease injury with two major objectives: to design biomarkers to diagnose or predict risk and monitor the graft tissue lesions through non-invasive techniques such as peripheral blood analyses.

(2) to design new methods of immunosuppression and/or induction or detection of a state of immune tolerance and, in collaboration with the Cesti born companies and large pharmaceutical companies, to transfer applications to the clinical field in the context of vascularized organ and hematopoietic stem cell transplantation or even in preliminary trials of cell or vectorized gene transplantation,

(3) to widen the access to transplantation through an improvement in current clinical approaches but also through innovative and futurist “new frontier” approaches, such as cell therapy, including xenogeneic source and gene therapy for gene defects, or gene therapy-based manipulation of the recipient immune system or donor tissues.